A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Myelogenous Leukemia, Chronic Clinical Trial

Official title:

Phase II Study of Flumatinib Versus Imatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01503502
• Other study ID #: HHGV678-201
• Status: Active, not recruiting
• Phase: Phase 2
• First received: January 1, 2012
• Last updated: April 9, 2013
• Start date: August 2011
• Est. completion date: December 2014

Study information

• Verified date: April 2013
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

It is an open-label, randomized, multi-center study. The efficacy and safety of two flumatinib doses, 400 mg once daily and 600 mg once daily, will be compared with imatinib 400 mg once daily in newly diagnosed (within 6 months) patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

Description:

It is an open-label, randomized, multi-center study in comparison of Gleevec and flumatinib in newly diagnosed (within 6 months) CML patients who are Philadelphia chromosome-positive. One hundred and fifty adult patients will be randomized in 1:1:1 ratio. The planned doses are as follows: 400 mg QD (50 patients) of flumatinib, 600 mg QD (50 patients) of flumatinib, and 400 mg QD (50 patients) of imatinib. Flumatinib will be dosed, based on the food effect results, in fasting condition. Imatinib will be dosed with food per the package insert. The study consists of 2 phases: 6 months of core phase and 6 months of extension phase.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: December 2014
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female patients = 18 years and = 75 years of age.

2. ECOG 0, 1, or 2.

3. Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome.

4. Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.

5. Adequate end organ function as defined by:

1. Total bilirubin < 1.5 x ULN,

2. SGOT and SGPT < 2.5 x ULN,

3. Creatinine < 1.5 x ULN,

4. Serum amylase and lipase = 1.5 x ULN,

5. Alkaline phosphatase = 2.5 x ULN unless considered tumor related.

And patients must have the following laboratory values (= LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):

1. Potassium = LLN,

2. Magnesium = LLN,

3. Phosphorus = LLN,

4. Total calcium (corrected for serum albumin) = LLN.

6. Signed informed consent.

Exclusion Criteria:

1. Previously documented T315I mutations.

2. Any medical treatment for CML prior to study entry with the exception of hydroxyurea and/or anagrelide. Treatment with tyrosine kinase inhibitor(s) prior to study entry is not allowed.

3. Treatment with other investigational agents (defined as not used in accordance with the approved indication ) within 4 weeks prior to randomization.

4. Major surgery within 4 weeks prior to randomization or who have not recovered from prior surgery.

5. Impaired cardiac function including any one of the following:

1. History of unstable angina.

2. History of clinically documented myocardial infarction (during the last 12 month).

3. LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by locally read echocardiogram.

4. Inability to determine the QT interval on ECG.

5. Complete left bundle branch block.

6. Use of a ventricular-paced pacemaker.

7. Congenital long QT syndrome or a known family history of long QT syndrome.

8. History of or presence of clinically significant ventricular, atrial tachyarrhythmias, or QTcF > 450 msec for male or 470 msec for female.

6. Patients with active, uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders.

7. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).

8. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).

9. History of significant congenital or acquired bleeding disorder unrelated to cancer.

10. History of chronic pancreatitis or history of acute pancreatitis within 1 year of study entry.

11. Patients with another primary malignancy.

12. Acute or chronic uncontrolled liver or severe renal disease considered unrelated to disease.

13. Known to be allergic to the study drugs, including crude drug or adjuvant.

14. Patients actively receiving therapy with strong CYP3A4 inhibitors, strong CYP3A4 inducers or any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.

15. Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test within 7 days prior to Day 1 of study and (d) female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Abnormal Karyotype
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Myelogenous Leukemia, Chronic
• Philadelphia Chromosome

Intervention

Drug:
• flumatinib
Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
• imatinib
Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing	Beijing
China	Ruijin Hospital	Shanghai	Shanghai
China	The First Rffiurted Hospital of Soochow University	Suzhou	Jiangsu
China	Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College	Tianjin	Tianjin
China	Union Hospital Tongji Medical College Huazhong University of Science and technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare the rate of MMR at 6 months	Obtain major molecular response (MMR) rate at 6 months in newly diagnosed Ph+ CML patients through comparison of the efficacy results of flumatinib with that of imtinib.	6 months	No
Secondary	To compare the rate of MMR at 12 months		12 months	No